Orbis Medicines bags €90 million Series A
Orbis was founded in 2021 by the Seeds Investment team of Novo Holdings, the assets and wealth manager of the Novo Nordisk Foundation. The company...
Bremelanotide: Promising Diabetic Nephropathy Treatment
Palatin Technologies has announced topline results for the phase 2b Breakout study, which evaluated the effects of bremelanotide in patients with type 2 diabetic nephropathy....
Gilead taps into Terray’s AI-based drug discovery
According to the terms of the deal, Gilead will select a set of drug targets and Terray will discover and develop small molecule drugs that...
Brazil’s Nintx bags $10m for plant-based drugs
Founded by a team of scientists and healthcare specialists in 2021, Nintx harnesses compounds from Brazil’s world-famous plant ecosystems to develop treatments for complex, multifactorial...
AbbVie acquires Nimble for oral peptides
AbbVie and Nimble Therapeutics have announced an acquisition deal in which AbbVie will gain ownership of the company’s pipeline of oral peptide candidates. As part...
General Inception acquires Enable Medicine
The company creator General Inception (GI) has acquired Enable Medicine to pool its know-how regarding drug development and the biotech ecosystem with the latter’s biological...
Noema Pharma Secures $147M to Advance CNS Disorder Treatments
Noema Pharma has announced an extension of its series B financing round, bringing the total raised up to $147 million (CHF 130 million). The round...
Eli Lilly expansion set to add 750 skilled jobs to Wisconsin site
Shortly after acquiring a manufacturing site in Wisconsin, Eli Lilly intends to expand it to boost its production of injectable products, including diabetes and obesity...
AbbVie set to file for FDA approval on tavapadon
Pharma company, AbbVie, reports that its D1/D5 partial agonist, tavapadon, has met the primary and secondary endpoints in a pivotal Phase 3 trial. The trial,...
PTC Therapeutics boosted by Novartis rights deal for Huntington’s program
PTC Therapeutics announced this week that it has made a deal with Novartis for global rights to its oral Huntington’s disease candidate PTC518, a splicing...
Investment in radiopharmaceuticals is ramping up
Investment in radiopharmaceuticals is ramping up as big pharma shows a growing appetite for this promising drug modality. Radiopharmaceuticals see radioactive isotopes being delivered into...
Mitsubishi and Dewpoint team up to tackle ALS
The pharma arm of Mitsubishi Chemical Group has launched a collaboration with US-based Dewpoint Therapeutics to co-develop a preclinical-stage treatment for the neurological condition amyotrophic...
Körber absorbs Bähren to expand pharma packaging
The pharmaceutical business unit of the German giant Körber has snapped up the compatriot label and leaflet supplier Wilhelm Bähren GmbH & Co as the...
Novocure’s TTFields therapy boosts survival in pancreatic cancer
Swiss oncology specialist Novocure has announced positive topline results from the PANOVA-3 phase 3 clinical trial, which evaluated the use of tumor treating fields (TTFields)...
Tech-driven solutions for patient access
While these sites are important for clinical research, they make patient recruitment challenging. Many participants are forced to travel to these locations for recurring visits,...
Overcoming nonspecific binding challenges in PK assays
However, nonspecific binding (NSB) can hinder PK assays, impacting their accuracy and reliability. Fortunately, there are strategies and best practices to counter this issue. NSB...
Diabetes prevention – Eli Lilly’s Tirzepatide shows 23% weight loss
Eli Lilly has released detailed results from the SURMOUNT-1 phase 3 trial, where over 1,000 obese or overweight prediabetic participants were followed over the course...
Equity boost and partnership aim to accelerate GEMS platform’s efficiency
NVentures also participated in the company’s $200 million Series B last August. This strengthened collaboration is aimed at advancing Genesis’ capabilities to tackle complex and...
AstraZeneca invests $3.5BN to boost US manufacturing power
With around $2 billion of the investment dedicated to creating more than a thousand U.S. jobs, AstraZeneca is looking to expand R&D and manufacturing facilities...
FDA grants orphan drug designation to CervoMed’s dementia drug
The US company CervoMed announced yesterday that the FDA has granted Orphan Drug Designation to its oral investigational small molecule drug, Neflamapimod, for the treatment...